A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)
Xudong Zhang(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Shanshan Ma(First Affiliated Hospital of Zhengzhou University), Linan Zhu(First Affiliated Hospital of Zhengzhou University), Xiaorui Fu(First Affiliated Hospital of Zhengzhou University), Xin Li(Hubei University of Medicine), Xinhua Wang(Zhengzhou University), Lei Zhang(Union Hospital), Wenhua Wang(Lanzhou University), Jiaqin Yan(First Affiliated Hospital of Zhengzhou University), Ling Li(First Affiliated Hospital of Zhengzhou University), Mengke Fan(Hebei Medical University), Zhenchang Sun(First Affiliated Hospital of Zhengzhou University), Zhaoming Li(First Affiliated Hospital of Zhengzhou University)
Cited by 4
Related Papers
New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk
|Nature Communications|2016|318
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study
|The Lancet Infectious Diseases|2015|231
Metformin targets c-MYC oncogene to prevent prostate cancer
|Carcinogenesis|2013|141